Broadfin Capital’s Amicus Therapeutics FOLD Stock Holding History

Broadfin Capital’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-141,000	Closed	-$2.13M	–	48
2017 Q3	$2.13M	Buy	+141,000	New	+$1.87M	0.31%	43

Other funds holding FOLD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Broadfin Capital's FOLD Position: Q4 2017 in Review

Broadfin Capital sold out of Amicus Therapeutics (FOLD) in Q4 2017, closing a stake of 141,000 shares — an estimated $2.13M sold.

Broadfin Capital first reported a position in FOLD in Q3 2017 and held it in 1 quarter. The position peaked at $2.13M in Q3 2017. 185 funds tracked by Wall St. Rank hold FOLD as of Q4 2017.

Broadfin Capital reported no remaining Amicus Therapeutics position as of Q4 2017 after selling out during the quarter.
Broadfin Capital sold 141,000 Amicus Therapeutics shares in Q4 2017, an estimated $2.13M.
Broadfin Capital first reported a position in Amicus Therapeutics in Q3 2017 and held it in 1 quarter.
Broadfin Capital's Amicus Therapeutics position peaked at $2.13M in Q3 2017.
185 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2017.

Based on Broadfin Capital's 13F filing for Q4 2017, filed 13 Feb 2018.